Beyfortus approved in US for infant RSV prevention
17 July 2023 Beyfortus approved in the US for the prevention of RSVlower respiratory tract disease in infants First preventive option specifically designed to protectthe broad infant population through its first RSV season Across all clinical endpoints, a single dose of Beyfortus delivered consistent and sustained efficacy against RSV disease vs placebo AstraZeneca and Sanofi's Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their